First AD

Second AD

Prostate Cancer

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Immuno-Oncology

Genitourinary Cancers

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research. 

Oncology Business Management

 Oncology Business Management condition center page is a comprehensive resource for news and expert insights on business-focused updates and topics in oncology practices, including diversity efforts, telehealth, gaps in care, payment models, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates and best practices with oncology business management.

Precision Medicine in Oncology®

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Neal D. Shore, MD

OncLive News Network®

Symptomatic Bone Lesions in CRPC: More Options for Treatment

Combining and Sequencing Sipuleucel-T in CRPC

AUA2015: Biomarkers, Enzalutamide, and ARN509

Reassessing Trial Endpoints for CRPC

Administering Radium-223 for mCRPC

Reducing Skeletal-Related Events in Prostate Cancer

Asymptomatic Versus Symptomatic Bone Metastases in Prostate Cancer

Biomarkers Indicative of Bone Lesions in Prostate Cancer

Bone Metastases in CRPC: Prognostic for Survival